Candidiasis - Pipeline Review, H2 2016

Date: August 10, 2016
Pages: 151
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C1A9F76F89FEN
Leaflet:

Download PDF Leaflet

Candidiasis - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Candidiasis - Pipeline Review, H2 2016’, provides an overview of the Candidiasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Candidiasis
  • The report reviews pipeline therapeutics for Candidiasis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Candidiasis therapeutics and enlists all their major and minor projects
  • The report assesses Candidiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Candidiasis
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Candidiasis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Candidiasis Overview
Therapeutics Development
Pipeline Products for Candidiasis - Overview
Pipeline Products for Candidiasis - Comparative Analysis
Candidiasis - Therapeutics under Development by Companies
Candidiasis - Therapeutics under Investigation by Universities/Institutes
Candidiasis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Candidiasis - Products under Development by Companies
Candidiasis - Products under Investigation by Universities/Institutes
Candidiasis - Companies Involved in Therapeutics Development
Amplyx Pharmaceuticals, Inc.
Bakker Medical Srl
Biomar Microbial Technologies
Biosergen AS
Cellceutix Corporation
Cidara Therapeutics, Inc.
Daewoong Pharmaceutical Co., Ltd.
Dermala Inc
General Biologicals Corporation
Grupo Ferrer Internacional, S.A.
Hsiri Therapeutics, LLC
iCo Therapeutics Inc.
Matinas BioPharma Holdings, Inc.
Nanomerics Ltd
Novabiotics Limited
NovaDigm Therapeutics, Inc.
Onxeo SA
Scynexis, Inc.
Sealife PHARMA GMBH
TGV-Laboratories
Viamet Pharmaceuticals, Inc.
Wellstat Vaccines, LLC
Candidiasis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(clotrimazole + diclofenac sodium) - Drug Profile
(clotrimazole + diclofenac sodium) 1 - Drug Profile
61894700 - DRUG PROFILE
AC-17 - Drug Profile
amphotericin B - Drug Profile
amphotericin B - Drug Profile
amphotericin B - Drug Profile
Antibody to Target Ece1 for Candidiasis - Drug Profile
APX-001 - Drug Profile
arasertaconazole - Drug Profile
BSG-005 - Drug Profile
candidiasis vaccine - Drug Profile
CD-101 - Drug Profile
Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile
CTIX-1502 - Drug Profile
Drug for Candidiasis - Drug Profile
DWP-06081 - Drug Profile
Forazoline A - Drug Profile
iCo-010 - Drug Profile
KSL-W - Drug Profile
MH-010 - Drug Profile
miconazole nitrate - Drug Profile
Monoclonal Antibodies for Candidiasis - Drug Profile
Monoclonal Antibody for Candidiasis - Drug Profile
Monoclonal Antibody for Candidiasis and Gram-Positive Bacterial Infections - Drug Profile
Monoclonal Antibody to Inhibit the Beta-Glucan for Fungal Infections - Drug Profile
mutanobactins - Drug Profile
Myc-102 - Drug Profile
NDV-3 - Drug Profile
NDV-3A - Drug Profile
NP-339 - Drug Profile
obliquumol - Drug Profile
Occidiofungin - Drug Profile
PAC-113 - Drug Profile
PMX-1408 - Drug Profile
PMX-1570 - Drug Profile
PMX-1576 - Drug Profile
PMX-1591 - Drug Profile
PMX-1625 - Drug Profile
PMX-519 - Drug Profile
PMX-70004 - Drug Profile
Recombinant Peptides for Oropharyngeal Candidiasis - Drug Profile
SCY-078 - Drug Profile
SLP-0901 - Drug Profile
SLP-0904 - Drug Profile
Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile
Small Molecule for Fungal Infections - Drug Profile
Small Molecules for Aspergillosis and Candidiasis - Drug Profile
Small Molecules for Candidiasis - Drug Profile
Small Molecules for Candidiasis - Drug Profile
Small Molecules for Candidiasis - Drug Profile
Small Molecules for Fungal Infections - Drug Profile
Small Molecules for Fungal Infections - Drug Profile
Small Molecules for Systemic Candidiasis - Drug Profile
Synthetic Peptide to Inhibit CBL-B for Candidiasis - Drug Profile
Synthetic Peptides for Candidiasis - Drug Profile
Synthetic Peptides for Infections Diseases and Oncology - Drug Profile
TOL-463 - Drug Profile
Vaccine for Fungal Infections - Drug Profile
Vaccine to Target Ece1 for Candidiasis - Drug Profile
VT-1161 - Drug Profile
Candidiasis - Dormant Projects
Candidiasis - Discontinued Products
Candidiasis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Candidiasis, H2 2016
Number of Products under Development for Candidiasis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd.1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd.1)
Products under Development by Companies, H2 2016 (Contd.2)
Products under Investigation by Universities/Institutes, H2 2016
Candidiasis - Pipeline by Amplyx Pharmaceuticals, Inc., H2 2016
Candidiasis - Pipeline by Bakker Medical Srl, H2 2016
Candidiasis - Pipeline by Biomar Microbial Technologies, H2 2016
Candidiasis - Pipeline by Biosergen AS, H2 2016
Candidiasis - Pipeline by Cellceutix Corporation, H2 2016
Candidiasis - Pipeline by Cidara Therapeutics, Inc., H2 2016
Candidiasis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
Candidiasis - Pipeline by Dermala Inc, H2 2016
Candidiasis - Pipeline by General Biologicals Corporation, H2 2016
Candidiasis - Pipeline by Grupo Ferrer Internacional, S.A., H2 2016
Candidiasis - Pipeline by Hsiri Therapeutics, LLC, H2 2016
Candidiasis - Pipeline by iCo Therapeutics Inc., H2 2016
Candidiasis - Pipeline by Matinas BioPharma Holdings, Inc., H2 2016
Candidiasis - Pipeline by Nanomerics Ltd, H2 2016
Candidiasis - Pipeline by Novabiotics Limited, H2 2016
Candidiasis - Pipeline by NovaDigm Therapeutics, Inc., H2 2016
Candidiasis - Pipeline by Onxeo SA, H2 2016
Candidiasis - Pipeline by Scynexis, Inc., H2 2016
Candidiasis - Pipeline by Sealife PHARMA GMBH, H2 2016
Candidiasis - Pipeline by TGV-Laboratories, H2 2016
Candidiasis - Pipeline by Viamet Pharmaceuticals, Inc., H2 2016
Candidiasis - Pipeline by Wellstat Vaccines, LLC, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Candidiasis - Dormant Projects, H2 2016
Candidiasis - Dormant Projects (Contd.1), H2 2016
Candidiasis - Dormant Projects (Contd.2), H2 2016
Candidiasis - Dormant Projects (Contd.3), H2 2016
Candidiasis - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Candidiasis, H2 2016
Number of Products under Development for Candidiasis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

COMPANIES MENTIONED

Amplyx Pharmaceuticals, Inc.
Bakker Medical Srl
Biomar Microbial Technologies
Biosergen AS
Cellceutix Corporation
Cidara Therapeutics, Inc.
Daewoong Pharmaceutical Co., Ltd.
Dermala Inc
General Biologicals Corporation
Grupo Ferrer Internacional, S.A.
Hsiri Therapeutics, LLC
iCo Therapeutics Inc.
Matinas BioPharma Holdings, Inc.
Nanomerics Ltd
Novabiotics Limited
NovaDigm Therapeutics, Inc.
Onxeo SA
Scynexis, Inc.
Sealife PHARMA GMBH
TGV-Laboratories
Viamet Pharmaceuticals, Inc.
Wellstat Vaccines, LLC
Skip to top


Vulvovaginal Candidiasis - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 63 pages

Ask Your Question

Candidiasis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: